



of  $239 \times 10^3/\mu\text{l}$  (normal  $125\text{--}425 \times 10^3/\mu\text{l}$ ). Additional tests included an erythrocyte sedimentation rate of 106 mm/hour (normal  $<30$  mm/hour). Incision and drainage of a residual 2 cm abscess at the base of the thumb was undertaken in the outpatient and eventually discharged with surgical dressing, topical bacitracin, and doxycycline to be reviewed for serial wound dressing.

Two weeks later due to persistent drainage of the ulcer at the base of the left thumb, she was taken to the operating room for drainage of a left CMC joint abscess. Pus swabs were taken for both anaerobic and aerobic cultures and she was discharged on oral clindamycin. *Mycobacterium abscessus* Deoxyribonucleic acid was detected by real-time PCR with additional cultures growing the same organism within a week. Samples were sent to the New York State Department of Health for a full culture and sensitivity profile. On review 2 weeks after surgical drainage, she reported marked symptomatic improvement. A follow-up magnetic resonance imaging of the hand demonstrated severe osteoarthritic changes in the thumb CMC joint but no features of osteomyelitis with a focal thickening suspicious for a small developing abscess in contiguous tissue. A chest x-ray to screen for ongoing lung infection was also performed and it resulted negative for pulmonary disease. Final cultures resulted positive for *M. abscessus* resistant to ciprofloxacin, clarithromycin, doxycycline, imipenem, linezolid, moxifloxacin, trimethoprim/sulfamethoxazole, tobramycin, and susceptible to amikacin with intermediate susceptibility to cefoxitin.

She was started on clofazimine and omadacycline with subsequent orthopedic follow up and serial surveillance lab tests for medication side effects. After 6 months of therapy, she had total resolution of all symptoms with scar tissue at the base of her thumb.

## Discussion

We present a case of septic arthritis of the CMC joint of the left thumb in a 66-year-old American Caucasian woman with multidrug-resistant *M. abscessus*.

*Mycobacterium abscessus* belongs to non-tuberculous mycobacterium (NTM), particularly RGM which are environmental organisms found worldwide that usually grow in subcultures within a week [1,2]. They are known to cause pulmonary disease, lymphadenitis, disseminated disease, skin, and soft tissue infections, central nervous system infections, musculoskeletal infections, surgical site infections as well as prosthetic device infections [3]. Because of their resistance to disinfectants, they are potential causes of post-surgical and post-procedural infections [4]. There have been trends suggesting an increase in incidence and prevalence of NTM in the United States just like in other parts of the world with reported annual incidences ranging from 3.1 to 4.7, and prevalence increasing from 6.7 to 11.7 between 2008 and 2015 [4,5]. It is suspected

this could be largely attributed to increased surveillance and advancement of diagnostics.

Immunodeficiency is a well-documented driver of both tuberculous and non-tuberculous mycobacterial disease [6]. The patient we present had no underlying known immunodeficiency states such as HIV, chronic immunosuppressive therapy, diabetes, splenectomy, or chemotherapy. These are conditions that usually trigger suspicion in clinicians to investigate for both tuberculous and NTM disease potentially leading to under-diagnosis in patients considered low risk like the patient we present. Similar reports of RGM skin infections have been reported following mesotherapy injection inoculation similar to our patient who we believe was inoculated during an intra-articular steroid injection [7]. Similarly, two outbreaks of surgical wound infections traceable to particular hospitals in the Dominican Republic as well as Brazil have been reported [8,9].

Treatment options for *M. abscessus* depend on whether inoculates are macrolide sensitive or resistant. For macrolide-sensitive isolates, a macrolide with at least two more agents including a susceptible intravenous (IV) agent (amikacin/imipenem/cefoxitin) and omadacycline or tigecycline/tedizolid or linezolid/clofazimine is recommended. Evidence for the treatment of macrolide-resistant isolates is largely observational with commonly used regimens including: IV amikacin, IV imipenem, oral omadacycline, and clofazimine with macrolides occasionally added (despite resistance) to regimens in patients with background bronchiectasis. Duration of treatment ranges from 6 to 12 months depending on clinical response and the site of infection [10–12]

Our patient posed a clinical dilemma on the choice of drug therapy. Isolates from the cultures were resistant to quinolones, imipenem, doxycycline, and macrolides. Eventually, she was started on omadacycline and clofazimine for 6 months with complete symptom resolution.

The challenges of *M. abscessus* treatment have been described as an antibiotic nightmare by Nessar et al. [13]. This is due to the intrinsic resistance to not only the classical anti-tuberculous agents but also to most currently available antibiotics as well as acquired resistance to aminoglycosides and macrolides.

## Conclusion

This case not only highlights the importance of having a high degree of suspicion for *M. abscessus* in joint and soft tissue infections not improving to commonly used empirical therapies. It also underlines the importance of sample referral to specialized labs for treatment targeted cultures and sensitivity given formulation of antibiotic combinations for treatment of RGM including *M. abscessus* should be sensitivity guided.

### What is new?

*Mycobacterium abscessus* and other rapidly growing mycobacteria are potential causes of soft tissue infections even in non-endemic areas like North America. Having a high index of suspicion is important as these are often resistant not only to commonly used antibiotics but also to most anti-tuberculous agents.

### List of Abbreviations

CMC	Carpometacarpal
DNA	Deoxyribonucleic acid
IV	Intravenous
NTM	Non-tuberculous mycobacterium
PCR	Polymerase chain reaction
RGM	Rapidly growing mycobacterium

### Conflict of interest

The authors declare that they have no conflict of interest regarding the publication of this case report.

### Funding

None.

### Consent for publication

Written informed consent for publication of this case report and identifying images was obtained from the participant.

### Ethics approval and consent to participate

The case report was approved for publication by the United Health Services Hospitals Institutional Review Board, approval number: 13498.

### Author details

Frank Mulindwa<sup>1,2,3</sup>, Sana Chaudhary<sup>1</sup>, Jewel Estrella<sup>4</sup>, Vivek Kandanati<sup>1</sup>

1. United Health Services, Department of Internal Medicine, Wilson Hospital, New York, NY
2. Makerere University Infectious Diseases Institute, Kampala, Uganda
3. Global Health Institute, Antwerp University, Antwerp, Belgium
4. SUNY Upstate Medical School, New York, NY

### References

1. “Nontuberculous Mycobacteria (NTM) Infections | HAI | CDC.” [Online]. [cited 2024 Feb 26]. Available from: <https://www.cdc.gov/hai/organisms/nontuberculous-mycobacteria.html>
2. Sharma SK, Upadhyay V. Epidemiology, diagnosis & treatment of non-tuberculous mycobacterial diseases.

- Indian J Med Res. 2020 Sep;152(3):185–226. [https://doi.org/10.4103/ijmr.IJMR\\_902\\_20](https://doi.org/10.4103/ijmr.IJMR_902_20)
3. Wallace RJ Jr, Swenson JM, Silcox VA, Good RC, Tschen JA, Stone MS. Spectrum of disease due to rapidly growing mycobacteria. Rev Infect Dis. 1983;5(4):657–79. <https://doi.org/10.1093/clinids/5.4.657>
4. Prevots DR, Marshall JE, Wagner D, Morimoto K. Global epidemiology of nontuberculous mycobacterial pulmonary disease: a review. Clin Chest Med. 2023 Dec;44(4):675–721. <https://doi.org/10.1016/j.ccm.2023.08.012>
5. Winthrop KL, Marras TK, Adjemian J, Zhang H, Wang P, Zhang Q. Incidence and prevalence of nontuberculous mycobacterial lung disease in a large U.S. Managed Care Health Plan, 2008–2015. Ann Am Thorac Soc. 2020 Feb;17(2):178–85. <https://doi.org/10.1513/AnnalsATS.201804-236OC>
6. Collins FM. Mycobacterial disease, immunosuppression, and acquired immunodeficiency syndrome. Clin Microbiol Rev. 1989 Oct;2(4):360–77. <https://doi.org/10.1128/CMR.2.4.360>
7. Regnier S, Cambau E, Meningaud JP, Guihot A, Deforges L, Carbonne A, et al. Clinical management of rapidly growing mycobacterial cutaneous infections in patients after mesotherapy. Clin Infect Dis. 2009 Nov;49(9):1358–64. <https://doi.org/10.1086/606050>
8. Furuya EY, Paez A, Srinivasan A, Cooksey R, Augenbraun M, Baron M, et al. Outbreak of *Mycobacterium abscessus* wound infections among “lipotourists” from the United States who underwent abdominoplasty in the Dominican Republic. Clin Infect Dis. 2008 Apr;46(8):1181–8. <https://doi.org/10.1086/529191>
9. Duarte RS, Lourenço MC, Fonseca LS, Leão SC, Amorim EL, Rocha IL, et al. Epidemic of postsurgical infections caused by *Mycobacterium massiliense*. J Clin Microbiol. 2009 Jul;47(7):2149–55. <https://doi.org/10.1128/JCM.00027-09>
10. Daley CL, Glassroth J. Treatment of pulmonary nontuberculous mycobacterial infections: many questions remain. Ann Am Thorac Soc. 2014 Jan;11(1):96–7. <https://doi.org/10.1513/AnnalsATS.201311-399ED>
11. Kwak N, Dalcolmo MP, Daley CL, Eather G, Gayoso R, Hasegawa N, et al. *Mycobacterium abscessus* pulmonary disease: individual patient data meta-analysis. Eur Respir J. 2019 Jul;54(1):1801991. <https://doi.org/10.1183/13993003.01991-2018>
12. Jarand J, Levin A, Zhang L, Huit G, Mitchell JD, Daley CL. Clinical and microbiologic outcomes in patients receiving treatment for *Mycobacterium abscessus* pulmonary disease. Clin Infect Dis. 2011 Mar;52(5):565–71. <https://doi.org/10.1093/cid/ciq237>
13. Nessar R, Cambau E, Reyrat JM, Murray A, Gicquel B. *Mycobacterium abscessus*: a new antibiotic nightmare. J Antimicrob Chemother. 2012 Apr;67(4):810–8. <https://doi.org/10.1093/jac/dkr578>

### Summary of the case

1	Patient (gender, age)	Female, 66- year old
2	Final diagnosis	<i>Mycobacterium abscessus</i> septic arthritis
3	Symptoms	Non resolving left thumb cellulitis following an intra-articular steroid injection into the carpometacarpal (CMC) joint for osteoarthritis treatment
4	Medications	Omadacycline and clofazimine
5	Clinical procedure	Incision and drainage
6	Specialty	Infectious diseases